1. Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer
- Author
-
Wortman, B.G., Astreinidou, E., Laman, M.S., Steen-Banasik, E.M. van der, Lutgens, L.C.H.W., Westerveld, H., Koppe, F., Slot, A., Berg, H.A. van den, Nowee, M.E., Bijmolt, S., Stam, T.C., Zwanenburg, A.G., Mens, J.W.M., Jurgenliemk-Schulz, I.M., Snyers, A., Gillham, C.M., Weidner, N., Kommoss, S., Vandecasteele, K., Tomancova, V., Creutzberg, C.L., Nout, R.A., PORTEC Study Grp, Radiotherapie, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Radiotherapy, Targeted Gynaecologic Oncology (TARGON), and CCA - Cancer Treatment and Quality of Life
- Subjects
medicine.medical_specialty ,Dummy run ,CARCINOMA ,IMPACT ,medicine.medical_treatment ,Brachytherapy ,Risk profile ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Endometrial cancer ,RADIATION-THERAPY ,Medicine and Health Sciences ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical physics ,DOSE-RATE BRACHYTHERAPY ,Protocol (science) ,OUTCOMES ,business.industry ,Other Research Radboud Institute for Health Sciences [Radboudumc 0] ,Hematology ,medicine.disease ,Checklist ,Quality assurance ,Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] ,Endometrial Neoplasms ,Oncology ,Radiology Nuclear Medicine and imaging ,030220 oncology & carcinogenesis ,Vagina ,Female ,Vaginal apex ,business ,Adjuvant ,RADIOTHERAPY - Abstract
Contains fulltext : 229838.pdf (Publisher’s version ) (Open Access) OBJECTIVE: The PORTEC-4a trial investigates molecular-integrated risk profile guided adjuvant treatment for endometrial cancer. The quality assurance programme included a dummy run for vaginal brachytherapy prior to site activation, and annual quality assurance to verify protocol adherence. Aims of this study were to evaluate vaginal brachytherapy quality and protocol adherence. METHODS: For the dummy run, institutes were invited to create a brachytherapy plan on a provided CT-scan with the applicator in situ. For annual quality assurance, institutes provided data of one randomly selected brachytherapy case. A brachytherapy panel reviewed and scored the brachytherapy plans according to a checklist. RESULTS: At the dummy run, 15 out of 21 (71.4%) institutes needed adjustments of delineation or planning. After adjustments, the mean dose at the vaginal apex (protocol: 100%; 7 Gy) decreased from 100.7% to 99.9% and range and standard deviation (SD) narrowed from 83.6-135.1 to 96.4-101.4 and 8.8 to 1.1, respectively. At annual quality assurance, 22 out of 27 (81.5%) cases had no or minor and 5 out of 27 (18.5%) major deviations. Most deviations were related to delineation, mean dose at the vaginal apex (98.0%, 74.7-114.2, SD 7.6) or reference volume length. CONCLUSIONS: Most feedback during the brachytherapy quality assurance procedure of the PORTEC-4a trial was related to delineation, dose at the vaginal apex and the reference volume length. Annual quality assurance is essential to promote protocol compliance, ensuring high quality vaginal brachytherapy in all participating institutes.
- Published
- 2021